RCA
BSX icon

Runnymede Capital Advisors’s Boston Scientific BSX Stock Holding History

Runnymede Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,719
Closed -$927K – 83
2025
Q4 		$927K Buy
+9,719
New +$953K 0.53% 53

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Runnymede Capital Advisors's BSX Position: Q1 2026 in Review

Runnymede Capital Advisors sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 9,719 shares — an estimated $927K sold.

Runnymede Capital Advisors first reported a position in BSX in Q4 2025 and held it in 1 quarter. The position peaked at $927K in Q4 2025. 1,667 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Runnymede Capital Advisors reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
  • Runnymede Capital Advisors sold 9,719 Boston Scientific shares in Q1 2026, an estimated $927K.
  • Runnymede Capital Advisors first reported a position in Boston Scientific in Q4 2025 and held it in 1 quarter.
  • Runnymede Capital Advisors's Boston Scientific position peaked at $927K in Q4 2025.
  • 1,667 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Runnymede Capital Advisors's 13F filing for Q1 2026, filed 14 Apr 2026.